Toxin profiles and antimicrobial resistance patterns among toxigenic clinical isolates of Clostridioides (Clostridium) difficile

Document Type: Original Article

Authors

1 Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

4 Bioinformatics and Computational Biology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Objective(s): Clostridioides (Clostridium) difficile infection as a healthcare-associated infection can cause life-threatening infectious diarrhea in hospitalized patients. The aim of this study was to investigate the toxin profiles and antimicrobial resistance patterns of C. difficile isolates obtained from hospitalized patients in Shiraz, Iran.
Materials and Methods: This study was performed on 45 toxigenic C. difficile isolates. Determination of toxin profiles was done using polymerase chain reaction method. Antimicrobial susceptibility to vancomycin, metronidazole, clindamycin, tetracycline, moxifloxacin, and chloramphenicol was determined by the agar dilution method. The genes encoding antibiotic resistance were detected by the standard procedures.
Results: The most frequent toxin profile was tcdA+, tcdB+, cdtAˉ, cdtBˉ (82.2%), and only one isolate harboured all toxin associated genes (tcdA+, tcdB+, cdtA+, cdtB+) (2.2%). The genes encoding CDT (binary toxin) were also found in six (13.3%) isolates. Resistance to tetracycline, clindamycin and moxifloxacin was observed in 66.7%, 60% and 42.2% of the isolates, respectively. None of the strains showed resistance to other antibiotics. The distribution of the ermB gene (the gene encoding resistance to clindamycin) was 57.8% and the tetM and tetW genes (the genes encoding resistance to tetracycline) were found in 62.2% and 13.3% of the isolates, respectively. The substitutions Thr82 to Ile in GyrA and Asp426 to Asn in GyrB were seen in moxifloxacin resistant isolates.
Conclusion: Our data contributes to the present understanding of virulence and resistance traits amongst the isolates. Infection control strategies should be implemented carefully in order to curb the dissemination of C. difficile strains in hospital.

Keywords

Main Subjects


1. Berger FK, Rasheed SS, Araj GF, Mahfouz R, Rimmani HH, Karaoui WR, et al. Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon. Int J Med Microbiol 2018; 308:358-363.
2. Lim SC, Androga GO, Knight DR, Moono P, Foster NF, Riley TV. Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. Int J Antimicrob Agents 2018; 52:411-415.
3. Janoir C. Virulence factors of Clostridium difficile and their role during infection. Anaerobe 2016; 37:13-24.
4. Aktories K, Papatheodorou P, Schwan C. Binary Clostridium difficile toxin (CDT) - a virulence factor disturbing the cytoskeleton. Anaerobe 2018; 53:21-29.
5. Tokimatsu I, Shigemura K, Osawa K, Kinugawa S, Kitagawa K, Nakanishi N, et al. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: results of a nationwide study in Japan. J Infect Chemother 2018; 24:641-647.
6. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307-312.
7. Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009; 34:516-522.
8. Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, et al. Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J Clin Microbiol 2017; 55:1998-2008.
9. Abuderman AA, Mateen A, Syed R, Sawsan Aloahd M. Molecular characterization of Clostridium difficile isolated from carriage and association of its pathogenicity to prevalent toxic genes. Microb Pathog 2018; 120:1-7.
10. Yang J, Zhang X, Liu X, Cai L, Feng P, Wang X, et al. Antimicrobial susceptibility of Clostridium difficile isolates from ICU colonized patients revealed alert to ST-37 (RT 017) isolates. Diagn Microbiol Infect Dis 2017; 89:161-163.
11. Spigaglia P, Mastrantonio P. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol 2004; 53:1129-1136.
12. Sedigh Ebrahim-Saraie H, Heidari H, Amanati A, BazarganiA, Alireza Taghavi S, Nikokar I, et al. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran. Infez Med 2018; 26: 308-315.
13. Jamal W, Pauline E, Rotimi V. A prospective study of community-associated Clostridium difficile infection in Kuwait: epidemiology and ribotypes. Anaerobe 2015; 35:28-32.
14. Jamal WY, Rotimi VO. Surveillance of antibiotic resistance among hospital- and community-acquired toxigenic Clostridium difficile isolates over 5-year period in Kuwait. PLoS One 2016; 11:e0161411.
15. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004; 42:5710-5714.
16. Terhes G, Urban E, Soki J, Hamid KA, Nagy E. Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004; 42:4316-4318.
17. Wayne PA. Performance standards for antimicrobial susceptibility testing. Clinical and laboratory standards institute (CLSI) 28th informational supplement. 2018: M100-S28.
18. The european committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters, version 8, 2018. http://www.eucast.org/clinical_breakpoints/.
19. Trinh S, Reysset G. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J Clin Microbiol 1996; 34:2078-2084.
20. Fry PR, Thakur S, Abley M, Gebreyes WA. Antimicrobial resistance, toxinotype, and genotypic profiling of Clostridium difficile isolates of swine origin. J Clin Microbiol 2012; 50:2366-2372.
21. Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmee M, et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57:784-789.
22. Karlowsky JA, Adam HJ, Kosowan T, Baxter MR, Nichol KA, Laing NM, et al. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015. Diagn Microbiol Infect Dis 2018; 91:105-111.
23. Costa CL, Mano de Carvalho CB, Gonzalez RH, Gifoni MAC, Ribeiro RA, Quesada-Gomez C, et al. Molecular epidemiology of Clostridium difficile infection in a Brazilian cancer hospital. Anaerobe 2017; 48:232-236.
24. Weber I, Riera E, Deniz C, Perez JL, Oliver A, Mena A. Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain. Int J Med Microbiol 2013; 303:128-133.
25. Vaishnavi C, Singh M, Mahmood S, Kochhar R. Prevalence and molecular types of Clostridium difficile isolates from faecal specimens of patients in a tertiary care centre. J Med Microbiol 2015; 64:1297-1304.
26. Rezazadeh Zarandi E, Mansouri S, Nakhaee N, Sarafzadeh F, Iranmanesh Z, Moradi M. Frequency of antibiotic associated diarrhea caused by Clostridium difficile among hospitalized patients in intensive care unit, Kerman, Iran. Gastroenterol Hepatol Bed Bench 2017; 10:229-234.
27. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42:1933-1939.
28. Krutova M, Nyc O, Matejkova J, Allerberger F, Wilcox MH, Kuijper EJ. Molecular characterisation of Czech Clostridium difficile isolates collected in 2013-2015. Int J Med Microbiol 2016; 306:479-485.
29. Cejas D, Rios Osorio NR, Quiros R, Sadorin R, Berger MA, Gutkind G, et al. Detection and molecular characterization of Clostridium difficile ST 1 in Buenos Aires, Argentina. Anaerobe 2018; 49:14-17.
30. Liu XS, Li WG, Zhang WZ, Wu Y, Lu JX. Molecular characterization of Clostridium difficile isolates in China from 2010 to 2015. Front Microbiol 2018; 9:845-852.
31. Luo Y, Zhang W, Cheng JW, Xiao M, Sun GR, Guo CJ, et al. Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong province, China. Infect Drug Resist 2018; 11:489-500.
32. Peng Z, Addisu A, Alrabaa S, Sun X. Antibiotic resistance and toxin production of Clostridium difficile isolates from the hospitalized patients in a large hospital in Florida. Front Microbiol 2017; 8:2584-2591.
33. Androga GO, Knight DR, Lim SC, Foster NF, Riley TV. Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes. Anaerobe 2018; 54:55-60.
34. Jimenez A, Araya R, Paniagua D, Camacho-Mora Z, Du T, Golding GR, et al. Molecular epidemiology and antimicrobial resistance of Clostridium difficile in a national geriatric hospital in Costa Rica. J Hosp Infect 2018; 99:475-480.
35. Gao Q, Wu S, Huang H, Ni Y, Chen Y, Hu Y, et al. Toxin profiles, PCR ribotypes and resistance patterns of Clostridium difficile: a multicentre study in China, 2012-2013. Int J Antimicrob Agents 2016; 48:736-739.
36. Hidalgo-Villeda F, Tzoc E, Torres L, Bu E, Rodriguez C, Quesada-Gomez C. Diversity of multidrug-resistant epidemic Clostridium difficile NAP1/RT027/ST01 strains in tertiary hospitals from Honduras. Anaerobe 2018; 52:75-78.
37. Rodriguez C, Fernandez J, Van Broeck J, Taminiau B, Avesani V, Boga JA, et al. Clostridium difficile presence in Spanish and Belgian hospitals. Microb Pathog 2016; 100:141-148.
38. Hampikyan H, Bingol EB, Muratoglu K, Akkaya E, Cetin O, Colak H. The prevalence of Clostridium difficile in cattle and sheep carcasses and the antibiotic susceptibility of isolates. Meat Sci 2018; 139:120-124.
39. Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, et al. Antimicrobial susceptibility of Clostridium difficile clinical isolates in Iran. Iran Red Crescent Med J 2013; 15:704-711.
40. Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, et al. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014. Clin Microbiol Infect 2018; 24:724-731.
41. Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 2015; 21:248 e249-248 e216.
42. Kuwata Y, Tanimoto S, Sawabe E, Shima M, Takahashi Y, Ushizawa H, et al. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan. Eur J Clin Microbiol Infect Dis 2015; 34:763-772.
43. Cheng JW, Yang QW, Xiao M, Yu SY, Zhou ML, Kudinha T, et al. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. J Microbiol Immunol Infect 2018; 51:411-416.